- Who We Are
Profile and Organization
- Our Vision & Strategy
- Our Values
- Inclusion & Diversity
- Our Contributions
- Team Bayer
- Bayer Worldwide
- Corporate Compliance
- Contact Us
William N. (Bill) Anderson has been a member of the Board of Management of Bayer AG since April 1, 2023. As announced in February, he was appointed by the Supervisory Board to become CEO of Bayer, effective June 1, 2023.
Bill Anderson was born on August 23, 1966 in Ohio, Texas, USA. He holds a Bachelor of Science degree from the University of Texas and a Master of Science degree from the Massachusetts Institute of Technology (MIT), both in Chemical Engineering. He also holds a Master of Science in Management from MIT’s Sloan School.
Bill started his professional career in 1989 at Ethyl Corporation, a U.S.-based specialty chemical company, with postings in Belgium and the Netherlands. In 1995, he joined Raychem Corporation, a U.S.-based material science and electronics firm. In 1997, Bill moved to Biogen, an American biotechnology firm, as a finance manager. He then became GM of the UK affiliate and eventually Vice President of Biogen’s Neurology Unit. Bill joined Genentech, a pioneering biotechnology company, in 2006, eventually serving as Senior Vice President of the firm’s oncology business.
In 2013, he joined Roche Pharmaceuticals, the parent company of Genentech, as Head of Global Product Strategy and Chief Marketing Officer. In 2016, he moved back to Genentech to assume the position of Head of North American Operations before becoming CEO of the company in 2017. In 2019, Bill became CEO of Roche Pharmaceuticals based in Switzerland.
Bill Anderson is married and has three adult children.